title: Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors.
abstract: The aim of this study is to investigate the prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV) in maintenance hemodialysis (HD) and continuous ambulatory peritoneal dialysis patients at the Rabat University Hospital and to identify the major risk factors for transmission. A retrospective study was performed in 67 chronic HD and 36 peritoneal dialysis patients. For the screening of viral infections, we tested for anti-HCV antibodies and HBs antigen (Hbs Ag). We compared infected and non-infected patients in order to determine the risk factors for contamination. In the HD unit, the prevalence of anti-HCV was 60% and the prevalence of HBs Ag was 6%. Duration of dialysis (P = 0.001) was the only risk factor in our HD patients. In peritoneal dialysis (PD), the prevalence of anti-HCV was 8%. Hbs Ag was detected in 2.6% of our PD patients. Viral hepatitis C is the main viral infection in our HD unit. The duration of dialysis is the main risk factor for infection in our study. The transmission is essentially nosocomial, requiring a strict adherence to infection control procedures.
authors.affiliation: Department of Nephrology, Dialysis and Renal Transplantation, Ibn Sina Hospital, Rabat, Morocco.
authors.forename: Zineb
authors.initials: Z
authors.lastname: Lioussfi
authors.forename: Zineb
authors.initials: Z
authors.lastname: Errami
authors.forename: Aicha
authors.initials: A
authors.lastname: Radoui
authors.forename: Hakima
authors.initials: H
authors.lastname: Rhou
authors.forename: Fatima
authors.initials: F
authors.lastname: Ezzaitouni
authors.forename: Naima
authors.initials: N
authors.lastname: Ouzeddoun
authors.forename: Rabea
authors.initials: R
authors.lastname: Bayahia
authors.forename: Loubna
authors.initials: L
authors.lastname: Benamar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D003428:Cross Infection / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006526:Hepatitis C / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D018937:Hepatitis C Antibodies / Q000097:blood; D006785:Hospitals, University; D006801:Humans; D017053:Infection Control / Q000379:methods; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009018:Morocco / Q000453:epidemiology; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies